The treatment of patients with acute coronary syndromes is straightforwardin principle but complex in practice. With the increase in referralsof moderate- or high-risk patients for invasive cardiac proceduresto improve clinical outcomes,1 there is a need to define theantithrombotic regimen that is optimal for both stabilizingthe underlying active atherosclerotic plaque and minimizingthe risk of bleeding.
The Acute Catheterization and Urgent Intervention Triage Strategy(ACUITY) trial, reported in this issue of the Journal,2 evaluatedthe role of a thrombin-specific anticoagulant — bivalirudin— as part of a blended medical and invasive strategy forpatients with acute . . . [Full Text of this Article]
Source Information
From the Ocala Heart Institute, Munroe Regional Medical Center, Ocala, FL.
This article has been cited by other articles:
Lincoff, A. M., Steinhubl, S. R., Manoukian, S. V., Chew, D., Pollack, C. V. Jr, Feit, F., Ware, J. H., Bertrand, M. E., Ohman, E. M., Desmet, W., Cox, D. A., Mehran, R., Stone, G. W., for the ACUITY of Trial Investigators*,
(2008). Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. J Am Coll Cardiol Intv
1: 639-648
[Abstract][Full Text]
(2006). Is Bivalirudin a Good Antithrombotic Choice in ACS Patients?. Journal Watch Cardiology
2006: 1-1
[Full Text]
Previous
